Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous BCMA/TACI-targeted CAR T cells AUTO2

A preparation of autologous T lymphocytes that are genetically engineered to contain a dual-targeted chimeric antigen receptor (CAR), which includes the natural protein a proliferation-inducing ligand (APRIL; TNFSF13), that targets the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; TNFRSF17) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI; TNFRSF13B), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous BCMA/TACI-targeted CAR T cells AUTO2 bind to BCMA and TACI expressed on tumor cells and induce selective cytotoxicity in those cells. In addition, AUTO2 carries the universal RQR8 safety "off" switch, which allows selective removal of the T cells through both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) following administration of rituximab if unacceptable side-effects occur.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:APRIL CAR T cells (AUTO2) targeting BCMA and TACI
APRIL CAR T cells targeting BCMA and TACI
autologous APRIL CAR T cells
autologous CAR T product AUTO2
Code name:AUTO 2
AUTO2
SUB-96123
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search